Cardiac surgery in a patient with haemophilia A

Thoracic and Cardiovascular Surgeon

Volumn 54, Issue 3, 2006, Pages 212-214

  Eren, Aida ^a,b   Friedl, R ^a   Hannekum, A ^a   Gulbins, H ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b NONE   (Germany)

Author keywords

Cardiac surgery; Factor VIII substitution; Haemophilia A

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADULT; ARTICLE; BLEEDING; CASE REPORT; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; EXTUBATION; HEART REHABILITATION; HEART SURGERY; HEMOPHILIA A; HUMAN; LABORATORY TEST; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; THORAX DRAINAGE; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; BIOLOGICAL MARKERS; COMBINED MODALITY THERAPY; CORONARY ARTERY BYPASS; CORONARY STENOSIS; FACTOR VIII; HEMOPHILIA A; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION;

EID: 33646450094     PISSN: 01716425     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-872859     Document Type: Article

References (8)

1. Rosendaal FR, Varekamp I, Smit C et al. Mortality and causes of death in Dutch haemophiliacs. 1973-86. Br J Haematol 1989; 71: 71-76
2. Rizza CR, Spooner RJD. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the directors of haemophilia centres in the United Kingdom. Br Med J 1983; 286: 929-933
3. Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol 1994; 88: 601-607
4. Stieltjes N, Altisent C, Auerswald G, Negrier C, Pouzol P, Reynaud J, Roussel G, Savidge F, Villar A, Schulman S. Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience. Haemophilia 2004; 9: 452-458
5. Sennett MM, Alarcon AP. Successful use of ReFacto continuous infusion in two paediatric patients with severe haemophilia A undergoing orthopaedic surgery. Haemophilia 2004; 9: 655-660
6. Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery. Haemophilia 1995; 1 (Suppl 1): 8-13
7. Lee C The use of recombinant Factor VIII products in previously treated patients with haemophilia A: pharmacokinetics, efficacy, safety, and inhibitor development. Semin Thromb Hemost 2002; 28: 241-246
8. Negrier C, Goudement J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group: factor eight bypassing activity. Thromb Haemost 1997; 77: 1113-1119